Up 19% today alone. Monogen.
stockhouse.ca
investorvillage.com
Re: Monogen Due Diligence Summary Lung Cancer from saliva
Thanks for the comprehensive post concerning MonoGen. I too have followed this stock for more than a year and have been anxiously waiting for its amazing story to unfold and for investors to comprehend this company's unseemingly limitless upside. At this point in time, the MonoPrep processor is about to hit the market with sales to begin later this year. As has been discussed, the stock is not followed by analysts or brokerage firms but that will all change when MonoGen is listed on the NASDAQ later this year. Today, MonoGen clearly presents an opportunity to purchase a quality company at a significant discount to its unrealized value for the following reasons:
1. Management.
The Company is run by the highest quality individuals. A close look at the history and backgrounds of senior management is second to none. Further, as described by the investors who attended the meeting in Chicago on January 11, 2007, these individuals are good persons who feel strongly about the company and its objective to become the leading cytology specimen processing company in the gynecological market and a major player in the molecular diagnostics market.
2. MonoPrep Processor.
The MonoPrep processor is the state of the art device in detecting cervical cancer, infectious diseases and other cancers at the cellular level before the disease/cancer has an opportunity to wreak havoc on the human body. The MonoPrep processor is clearly superior to the Thinprep 2000 or 3000 and it is only a matter of time before MonoGen becomes the leading medical diagnostic device to detect cervical cancer. Labs are not going to continue to purchase the Thinprep 2000 or 3000 which is not only inferior to the MonoPrep processor but they are limited to cervical cancer detection. The MonoPrep processor with the use of its Molecular Diagnostics Module can be used to detect other cancers, HPV and other infectious diseases from the same sample.For the competitive advantages of the MonoPrep processor see pages 56-57 Notice of Meeting and Information Circular dated September 13, 2006.
3. Intellectual Property.
MonoGen has over 300 patents which protect competitors from invading their market space. Furhermore, through the efforts of Dr. Norm Pressman MonGen retains patents on various manufacturing processes that apply to labs and manufacturing co's in the medical field and abroad. As has been discussed, MonoGen has patented panel assays for the detection of bladder, lung and colorectal cancers. It has had discussions with biotecnology co's to co-develop these panel assays along with its test to detect lung cancer from a sputum sample. How many individuals in North America could benefit from the earlier detction of lung cancer from such a simple test? More American's die of lung cancer than from breast,prostate and colorectal cancers combined. Early detection of lung cancer is crucial. The panel assays also include tests for breast, prostate and other cancers. For further details concerning MonoGen's patents you can search them at uspto.gov
4. Molecular Diagnostics.
The molecular diagnostics market was estimated at 1.4 billion in 2004 growing to 5.1 billion in 2009. Multi-billion dollar corporations are itching to jump in to this space as evidenced by GE Healthcare's $9.5 billion acquisition of Amersham; Siemens $5 billion acquisition of Bayer AG Diagnostics; as well
as Becton Dickinson's recent purchase of Tripath.
5. Orphan Stock.
This orphan stock will soon be adopted by analysts once the company begins marketing and selling its MonoPrep processor and consumables as well as obtains listing on the NASDAQ later this year. Until then, MonoGen' promise and potential will only be known to those close to the company. It presents an opportune time for the individual investor to buy into a quality company before retail US investors discover all this company's attributes.
6. Business Model.
MonoGen has a razor/razorblade business model based on recurring revenue with a gross profit margin of approximately 75%. It has also partnered with Cardinal Health(sales in excess of $75 billion) to sell and distribute its products to many of the labs that Cardinal Health is already doing business with and therefore providing a competitive edge.
7. Purpose.
MonoGen's state of the art products are directed for the purpose of detecting diseases and cancers at early stages to prevent the further spread of disease/cancer. I certainly feel more comfortable investing in a company like MonoGen knowing that as a result of the company's efforts lives can be lengthened and saved.
Good luck to all MonoGen investors.
|
